Amwell Announces New Chief Marketing Officer Susan Worthy

Industry veteran brings more than two decades of experience building and scaling effective marketing strategies for leading healthcare companies

April 27, 2022 – Boston, MA — Amwell® (NYSE: AMWL), a national telehealth leader, today announced Susan Worthy has joined the company as Chief Marketing Officer. Susan is a tenured marketing executive with more than 25 years of experience leading marketing for healthcare services and technology companies. In her new role, Susan will be responsible for leading Amwell’s overall marketing strategy and will play a pivotal part in building upon the company’s market position to drive continued growth, as well as shareholder and customer value.

“We are thrilled to have Susan join our executive team. Her impressive background combined with her creativity, data-driven approach and proven track record of working with and leading the marketing strategy for market leading companies, made it clear that she was the right person to further enhance our market differentiation, cross-functional go-to-market strategies and serve as a strategic partner,” said Brendan O’Grady, Chief Growth and Commercial Officer, Amwell. “As we continue to navigate through a time of great transformation for Amwell and for our industry, I am confident that Susan will have an immediate impact on our team and our ability to serve current and future customers.”

Susan joins Amwell from Optum, where she spent the past six years leading marketing teams, driving product value, and establishing thought leadership and market awareness to achieve growth and shareholder value. Prior to Optum, Susan served as a marketing leader for Aetna and Best Doctors (now Teladoc) as well as several other healthcare companies. Susan has a passion for brand storytelling and is highly regarded for her dynamic leadership and ability to build and motivate results-driven teams.

“Amwell has a long history of improving healthcare availability through the use of technology that results in better clinical and financial outcomes,” said Worthy. “I’m excited to be part of a company focused on digital health innovation that is driving new levels of access, care coordination, patient experience, and behavioral health support. I am looking forward to helping Amwell bring this story of differentiation and excellence to the market and contributing to the Company’s mission and journey.”

Susan succeeds Mary Modahl, who retires effective April 30, after helping to ensure a seamless transition.

“Mary has been a trusted partner throughout her 10+ years at Amwell. She has played an important role in shaping Amwell’s go-to-market strategy and organizational culture through our early growth phase. Our board and entire leadership team thank Mary for her contributions and wish her well as she enters this new chapter,” continued O’Grady.

About Amwell
Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives. For more information, please visit https://business.amwell.com/.

American Well, Amwell, Converge, SilverCloud, Conversa and Carepoint are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.

Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: weak growth and increased volatility in the telehealth market; inability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under ‘Risk Factors’ in our most recent form 10-K filed with the SEC. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of our website at investors.amwell.com and on the SEC’s website at www.sec.gov.

SOURCE: Amwell